Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Eli Lilly (LLY 3.74%) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” ...

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Eli Lilly & Co slashed the price of its blockbuster weight-loss and diabetes drug Mounjaro in China, intensifying competition ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

(Editor’s note: This story was written before Eli Manning was not included in the Pro Football Hall of Fame class of 2025.) Two guys are sitting in a bar. They could be talking about who the Giants’ ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the ...

Eli Lilly stays a Strong Buy as GLP-1 demand drives revenue/EPS beats, margin gains, and pipeline upside. Click here to read ...